Faculty, Staff and Student Publications
Publication Date
3-21-2025
Journal
iScience
Abstract
Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer with limited treatment options. Patients often respond well to initial chemo-immunotherapy but relapse quickly, necessitating new strategies to enhance immune responsiveness. Recent research explores combining DNA-damaging therapies with immunotherapy to activate the STING pathway and improve the antitumor immune response. The addition of DNA Damage Repair (DDR) inhibitors, such as DNA-PKcs inhibitors, after chemotherapy has shown promise in activating innate immune sensors and enhancing CD8
Keywords
Molecular biology, Cell biology, Cancer
DOI
10.1016/j.isci.2025.111943
PMID
40034862
PMCID
PMC11875153
PubMedCentral® Posted Date
2-1-2025
PubMedCentral® Full Text Version
Post-print
Graphical Abstract
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons